120 related articles for article (PubMed ID: 31381130)
1. Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty.
Montserrat E; Gale RP
Cancer; 2019 Nov; 125(21):3699-3705. PubMed ID: 31381130
[TBL] [Abstract][Full Text] [Related]
2.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
3. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
9. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
10. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
11. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
13. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Recchia AG; Rossi FM; Zucchetto A; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Jaksic O; Olivieri J; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E306-E310. PubMed ID: 33989438
[No Abstract] [Full Text] [Related]
14. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
15. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
16. Prognostication of chronic lymphocytic leukemia in the era of new agents.
Eichhorst B; Hallek M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
[TBL] [Abstract][Full Text] [Related]
17. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
18. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
[No Abstract] [Full Text] [Related]
19. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
Zenz T; Döhner H; Stilgenbauer S
Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
